INTRODUCTION AND OBJECTIVES: Holmium laser enucleation of the prostate (HoLEP) for the management of benign prostatic hyperplasia has two procedural steps: Enucleation of the adenoma and tissue morcellation. While a recent randomized trial evaluating the two currently available morcellators found no significant difference in morcellation efficiency an analysis of cost was not performed factoring in the expense of operating room (OR) time. Therefore, we aim to evaluate the true cost associated with each device in a matched cohort analysis.
METHODS: An institutional review board approved prospectively maintained database of HoLEP patients was utilized for this study. We evaluated all patients from 2013, the last year our institution exclusively used the VersaCut' morcellator a reusable blade device, and matched them 1:1 with the most recent patient cohort utilizing the Piranha morcellator, a disposable blade device. Statistical analysis utilizing student t-Test was performed evaluating differences in means regarding morcellation efficiency, cost of morcellation including the expense of OR time and disposable instrument costs. RESULTS: We identified 142 patients within our institutional database who underwent HoLEP in 2013 with the VersaCut device and matched them 1:1 to our most recent group of patients undergoing the same procedure with the Piranha. There were no statistically significant differences between the previous and most recent group with regards to patient age (69.8 versus 69.9 yrs, p¼0.9) and total enucleated tissue weight (72.8 versus 77.7g, p¼0.46), respectively. However, when compared with the Versacut group, morcellation efficiency (4.4 versus 7.0 g/min, p<0.01) and expense of OR time ($1420.80 versus $992.21, p<0.005) both favored the Pirahna morcellator system. When the costs of disposable instruments were factored into the analysis with OR time costs, total cost still favored the Pirahna morcellator ($1338.81versus $1637.50, p<0.05).
CONCLUSIONS: In a matched cohort comparing morcellation cost utilizing both the VersaCut' and Piranha morcellation devices, we identified a significant improved efficiency and improved cost savings utilizing the Piranha morcellator even when controlling for disposable costs. METHODS: We retrospectively reviewed the medical records of 393 patients who had undergone HoLEP for BPH. Those with prostate cancer diagnosed before or after HoLEP, a history of other prostatic and/or urethral surgery, moderate to severe postoperative complications, and neurogenic causes were excluded. Patients with SUI following HoLEP were included, and we divided the patients into two groups: the early recovery of SUI group and the persistent SUI group. Early recovery of SUI was defined as recovery of SUI within one month after HoLEP, and persistent SUI was defined as SUI is still present after one month. Preoperative clinical and urodynamic factors, as well as perioperative factors, were compared between groups.
Source of
RESULTS: SUI following HoLEP was found in 86 patients (86/ 393, 21.9%). Thirty-three patients (33/86, 38.4%) showed recovery of SUI within one month, and SUI was still present in 53 patients (53/86, 61.6%) after one month. The preoperative clinical characteristics and urodynamic parameters are shown in Table 1 . The transitional zone volume of prostate in the early recovery of SUI group was higher than that in the persistent SUI group. In a comparison of perioperative factors, enucleation ratio (enucleation weight/transitional zone volume) in the early recovery of SUI group was lower than that in the persistent SUI group. (0.65 AE 0.32 vs 0.9 AE 0.69, P ¼ 0.010) A multivariate analysis showed that the enucleation ratio (OR 4.252, , P ¼ 0.034) was significantly associated with the early recovery of SUI.
CONCLUSIONS: Persistent SUI for more than one month following HoLEP occurred in some patients, and the high enucleation ratio could be associated with it. These patients would need early management for SUI following HoLEP. . 197, No. 4S, Supplement, Saturday, May 13, 2017 
